By Nikki Kean
The FDA has approved the immunotherapeutic agent atezolizumab (Tecentriq, Genentech), in combination with the chemotherapy drugs carboplatin and etoposide, for the initial treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). This is the first new treatment option for this type of lung cancer in more than 20 years, according to a press release from the FDA.
MARCH 19, 2019